Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest Julia Paik is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability not applicable
Additional information about this Adis Drug Review can be found here
is a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor approved
for first-line maintenance treatment in adults with advanced ovarian cancer who
are in complete or partial response to first-line, platinum-based chemotherapy.
Originally approved as monotherapy, olaparib is also approved to be administered
in combination with bevacizumab in patients whose cancer is associated with
homologous recombination deficiency (HRD), defined by either a BRCA1/2 mutation and/or genomic
instability. In phase III trials, olaparib monotherapy significantly improved
progression-free survival (PFS) relative to placebo (SOLO-1), as did olaparib
plus bevacizumab relative to placebo plus bevacizumab (PAOLA-1), in patients
with advanced ovarian cancer who had responded to platinum-based chemotherapy.
In PAOLA-1, improvements in PFS with olaparib plus bevacizumab were not seen in
patients with HRD-negative tumours relative to placebo plus bevacizumab. Both olaparib monotherapy and olaparib in
combination with bevacizumab had generally manageable tolerability profiles. Olaparib,
alone or in combination with bevacizumab, is a useful option for the first-line
maintenance treatment of adults with HRD-positive, advanced epithelial ovarian,
fallopian tube or primary peritoneal cancer who are in complete or partial
response to first-line, platinum-based chemotherapy.
© Springer Nature Switzerland AG 2021